Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 7.5% – What’s Next?

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) rose 7.5% during mid-day trading on Thursday . The stock traded as high as $0.26 and last traded at $0.25. Approximately 33,566,019 shares traded hands during trading, a decline of 48% from the average daily volume of 64,815,828 shares. The stock had previously closed at $0.23.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a research report on Thursday, January 9th. They set a “hold” rating for the company.

Tonix Pharmaceuticals Stock Up 5.9 %

The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The stock’s 50-day moving average price is $0.26 and its 200-day moving average price is $0.31. The stock has a market cap of $45.97 million, a price-to-earnings ratio of 0.00 and a beta of 2.02.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The business had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $2.63 million. On average, sell-side analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.